Fri.May 01, 2020

article thumbnail

Oxford BioDynamics biomarker platform is selected to help identify COVID-19 patients at risk of severe disease and profile patients who will benefit from therapeutic treatment

Drug Discovery Today

Oxford BioDynamics’ EpiSwitch technology has been chosen as the biomarker platform for prognostic and predictive profiling of COVID-19 patients in the GETAFIX clinical study.Institute of Infection, Immunity and Inflammation, University of Glasgow, and NHS Scotland are leading the effort to identify patients at risk of severe immune complications and those patients who can benefit from treatment with the anti-viral favipiravir.The EpiSwitch platform has already delivered prognostic and predictive

article thumbnail

Trump’s Pakistani Imported Chloroquine Phosphate: FDA Inspections vs. EU Testing to Ensure Drug Safety

Pharmacy Checkers

In late March, drug giant Bayer Pharmaceuticals, out of the goodness of its heart, agreed to donate three million tablets of chloroquine phosphate to help the Trump administration get this drug into U.S. pharmacies. That’s according to an investigative article in Vanity Fair by Katherine Eban, called: “‘ Really Want to Flood NY and NJ’: Internal Documents Reveal Team Trump’s Chloroquine Master Plan”.

Drugs 53